SLAM BioTherapeutics
Slam Bio is a biotech company developing a platform of very promising first-in-class human antibody-drug conjugates (ADCs) and bispecific monoclonal antibodies targeting the most challenging blood cancer (MDS, AML, CTCL and FL).
Baccine
Baccine is developing a first-of-its-kind genetically engineered bacterial platform that will unleash anti-tumor immunity thereby giving new hope for cancer patients
Gnomica Biotherapy
Gnomica is developing small-molecule drug inhibitors targeting bacterial pathways to treat cancer.
Actithera Secures Exclusive Rights to Innovative Covalent Chemistry Technologies from Weizmann Institute for Targeted Radiopharmaceutical Applications
Exclusive license via Yeda to two Weizmann Institute patent families from Prof. Nir London's lab, a leader in covalent drug design
Site-specific, durable and traceless protein radiolabeling approaches intended to enhance tumor selectivity and retention in radiopharmaceuticals
Integration into Actithera's platform to support design of next-generation radioligand therapies across oncology indications
CLISEQ, 10X Genomics and Weizmann Institute to Investigate Single Cell Applications in Hematology Clinical Diagnostics
Introducing CLISEQ – a new spinoff from Yeda / Weizmann Institute of Science, with the bold vision of transforming hematology diagnostics.
Instead of relying on invasive bone marrow aspiration, CLISEQ is pioneering single-cell analysis from peripheral blood, aiming to improve outcomes for patients with hematologic disorders and unlock the next generation of blood profiling for diagnostics and monitoring.
Vyriad and Weizmann Institute of Science Enter Exclusive License Agreement for In Vivo Gene Delivery Technology
Exclusive license with Yeda Research and Development Company, Weizmann Institute’s commercial arm, broadens Vyriad’s delivery portfolio with a novel viral targeting approach designed to preserve potency, while improving specificity
Agreement brings together Weizmann’s discovery and Vyriad’s development expertise to expand strategies for safe, effective, and accessible in vivo therapies
KiteraIO
Kitera revolutionizes tree health and carbon assessment by offering a comprehensive system that gathers insights from within, around, and below trees.
SilkIt
SilkIt is a biotech company that specializes in biomaterials derived primarily from silk. Our breakthrough lies in a straightforward method for extracting fibroin (the silk protein) from silk cocoons.
Launch of Gnomica Biotherapy
We are proud to announce the launch of Gnomica Biotherapy, a new biotech company emerging from discoveries made in Ravid Straussman's lab at the Weizmann Institute of Science!
Gnomica is pioneering a novel approach to cancer treatment, developing small-molecule drug inhibitors targeting bacterial functions in the human body, a critical and often overlooked factor in treatment resistance.
Pages
